January 10, 2023

PCCA Introduces Innovative New Compounding Base – SuspendIt® Anhydrous

This patent-pending oral suspending vehicle offers a low water activity technology platform with improved physical characteristics , broader application and the potential for longer BUDs to compounding pharmacies

HOUSTON, Texas – January 10, 2023 – PCCA’s innovative new oral suspending base, SuspendIt Anhydrous, is ideal for active pharmaceutical ingredients (APIs) that are unstable in water or have incompatibilities with existing aqueous vehicles.

“An anhydrous base offers many benefits to compounding pharmacies,” PCCA Chief Scientific Officer Gus Bassani said. “There’s no water to support the growth of micro-organisms or cause hydrolytic degradation of an API and it opens the potential for formulations to be assigned longer beyond-use dates (BUDs). But what makes our new base really unique is its self-emulsifying properties. This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility as well.”

The majority of anhydrous bases currently on the market are oil-based; however, many patients — especially children — do not like the taste of oil-based vehicles, nor do they like the oily residue left in their mouths and throats. These and other issues lead to problems with medication compliance.

“We developed a unique anhydrous base that, in addition to the self-emulsifying properties, has an improved viscosity, which reduces when shaken and thickens when standing. This thixotropic effect allows for rapid redispersion of APIs with agitation and minimizes sedimentation,” PCCA Director of Research and Development Daniel Banov said. “We added a natural sweetener, as well as the ability to mix the compounded medicine with juice or water at the moment of administration, for a better taste if desired. The technology is so unique that we have a patent pending.”

Developing the unique anhydrous base was a collaborative effort. “Our Research and Development team, as well as our Formulations, Quality Control and Operations teams, collaborated, performing multiple uniformity and stability studies on SuspendIt Anhydrous. We also tested the base’s performance in nasogastric feeding tubes and were very pleased with the results,” Bassani said.

Additionally, PCCA has created formulas for the most commonly prescribed APIs and plans to continue formula development and API testing. Formulas and studies are available to PCCA members.

ABOUT PCCA

PCCA supports the creation of personalized medicine and innovative products that make a difference in patients’ lives. As a complete resource for independent compounding pharmacies and health systems, PCCA provides high-quality products, education and support to more than 3,000 pharmacy members throughout the United States, Canada, Australia and other countries around the world. Incorporated in 1981 by a network of pharmacists, PCCA has supported pharmacy compounding for more than 40 years.

MEDIA CONTACT

Kim Speairs, APR, MBA, Director of Communications, PCCA, 817.729.5064, kspeairs@pccarx.com